The MURANO study: final analysis and retreatment/crossover substudy results of VenR for patients with relapsed/refractory CLL

Journal:
Blood
Published:
Affiliations:
21
Authors:
22
Institutions Authors Share
Roche Products Limited, United Kingdom (UK)
4.000000
0.18
Amsterdam UMC, Netherlands
2.000000
0.09
AbbVie, United States of America (USA)
2.000000
0.09
UC San Diego Health Sciences, United States of America (USA)
1.000000
0.05
University of Cologne (UoC), Germany
1.000000
0.05
University of Calgary (U of C), Canada
1.000000
0.05
Sir Mortimer B. Davis Jewish General Hospital (SMBD JGH), Canada
1.000000
0.05
Columbia University Irving Medical Center (CUIMC), CU, United States of America (USA)
1.000000
0.05
Medical University of Lodz (MUL), Poland
1.000000
0.05
Hospital Universitario 12 de Octubre, Spain
1.000000
0.05
Medical University of Vienna (MUW), Austria
1.000000
0.05
Montpellier University Hospital, UM, France
1.000000
0.05
Niguarda Hospital, Italy
1.000000
0.05
Erasmus University Medical Center (Erasmus MC), Netherlands
1.000000
0.05
Genentech, Inc., United States of America (USA)
1.000000
0.05
Royal Hobart Hospital (RHH), Australia
0.500000
0.02
University of Tasmania (UTAS), Australia
0.500000
0.02
Royal Melbourne Hospital (RMH), Australia
0.333333
0.02
Peter MacCallum Cancer Centre (Peter Mac), Australia
0.333333
0.02
The University of Melbourne (UniMelb), Australia
0.333333
0.02